XELOX和OLF化疗方案治疗K-ras基因突变型老年晚期大肠癌的疗效分析被引量：20

Efficacy of XELOX and OLF chemotherapy in advanced colorectal cancer patients with KRAS gene mutations

下载PDF

导出

摘要目的比较分析K-ras基因突变型老年晚期大肠癌患者接受奥沙利铂联合卡培他滨(XELOX)和奥沙利铂联合氟尿嘧啶(OLF)化疗方案的疗效。方法分析2009年1月-2012年8月该院收治的经基因分析确诊为K-ras基因突变型晚期大肠癌病例,共106例。其中接受XELOX化疗者56例,接受OLF化疗者50例,并比较分析两组接受化疗后发生毒副反应、客观缓解率、疾病控制率、无进展生存期、总生存期的差异。结果O LF组骨髓抑制、恶心呕吐、静脉炎、心脏毒性的发生率高于XELO X组,而腹泻的发生率XELO X组要明显高于OLF组,在口腔炎及神经毒性的发生率上,两组差异无统计学意义。两组客观缓解率、疾病控制率、无进展生存期和总生存期差异无统计学意义。结论 XELOX治疗K-ras基因突变型老年晚期结肠癌具一定疗效,相对安全,可提高患者的生存质量。 Objective To investigate the clinical effect of XELOX and OLF chemotherapy in advanced colorectal cancer patients with KRAS gene mutations.Methods KRAS mutations were found in 106 colorectal cancer patients in our hospital from January 2009 to August 2012.Among them,56 cases received XELOX chemotherapy,50 cases received OLF chemotherapy.The toxic and side effects,objective response rate,disease control rate,progression-free survival,and overall survival were compared between the two groups after chemotherapy.Results The incidences of bone marrow suppression,nausea and vomiting,phlebitis,cardio-toxicity in the OLF group were higher than those in the XELOX group,while the incidence of diarrhea in the XELOX group was significantly higher than that in the OLF group.There was no significant difference in the incidence of stomatitis or neurotoxicity,objective response rate,disease control rate,progression-free survival or overall survival between the two groups.Conclusions Compared with OLF,XELOX appears to be a relatively safe and effective chemotherapy and can improve the patient＇s quality of life.

作者练英妮毛进星曾志坚陈玉兰高婷花黄金杜

机构地区广东省肇庆市第一人民医院肿瘤科

出处《中国现代医学杂志》 CAS 北大核心 2016年第2期51-54,共4页 China Journal of Modern Medicine

关键词 K-RAS基因大肠癌化学疗法 KRAS gene colorectal cancer chemotherapy

分类号 R735.3 [医药卫生—肿瘤]

引文网络
相关文献

参考文献14

1Jung KW, Won YJ, Kong HJ, et al. Cancer statistics in incidence, mortality, survival and prevalence in 2010[J]. Research and Treatment, 2013, 45(1): 1-14.
2Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, Korea: Cancer 2014[J].CA, 2014, 64(2): 104-117.
3Demes M, Seheil-Bertram S, Bartseh H, et al. Signature of mi- erosatellite instability, KRAS and BRAF gene mutations in Ger- man patients with locally advanced rectal adenoeareinoma before and after neoadjuvant 5-FU radioehemotherapy[J]. Journal of Gastrointestinal Oneology, 2013, 4(2): 182-192.
4Southward K, Hutehins G, Handley K, et al. K-ras mutation is a negative prognostic marker, and does not preclude benefit from 5-fu in stage l]/m eoloreetal cancer[C]. Journal of Pathology, 2011, 224: $4.
5National Cancer Institute. Common Terminology Criteria for Ad- verse Events (CTCAE) Version 4.02[S/OL]. (2009-09-15) [2011- 12-30].
6郭端英,姚吉龙,梁玉蝉,范群.KRAS和BRCA1/2基因突变状态对卵巢上皮癌患者预后的影响[J].中国现代医学杂志,2014,24(22):31-34. 被引量：1
7Schubbert S, Shannon K, Bollag G. Hyperactive ras in develop mental disorders and cancer[J]. Nature Reviews Cancer, 2007, 7(4): 295-308.
8Etienne-Grimaldi MC, Formento JL, Franeoual M, et al. K-Ras mutations and treatment outcome in eolorectal cancer patients re- ceiving exclusive fluoropyrimidine therapy[J]. Clinical Cancer Re- search, 2008, 14(15): 4830-4835.
9Carsten B, Igor B, Anatoly M, et al. Fluorouracil, leucovorin, and oxaliplatin with and without eetuximab in the first-line treatment of metastatic eoloreetal cancer[J]. Journal of Clinical Ontology, 2009, 27(5): 663-671.
10Li M, Liang Z, Sun X, et al. A polymeric prodrug of 5-fluo- rouracil-l-acetic acid using a multi-hydroxyl polyethylene glycol derivative as the drug carrier[J]. PLoS One, 2014, 9(11): e112888.

二级参考文献24

1HIGGINS MJ, BASELGA J. Targeted therapies for breast cancer [J]. The Journal of Clinical Investigation, 2011, 121(10): 3797- 3803.
2HANAHAN D, WEINBERG RA. The hallmarks of eaneer[J]. Cell, 2000, 100(1): 57-70.
3ARDIGHIERI L, ZEPPERNICK F, HANNIBAL CG, et al. Muta- tional analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants [J]. The Journal of Pathology, 2014, 232(1): 16-22.
4REUTER CWM, MORGAN MA, BERGMANN L. Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies[J]. Blood, 2000, 96(5): 1655-1669.
5KING MC, MARKS JH, MANDELL JB. Breast and ovarian can- cer risks due to inherited mutations in BRCA1 and BRCA2[J]. Scienee, 2003, 302(5645): 643-646.
6BROHET RM, VELTHUIZEN ME, HOGERVORST FBL, et al. Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BR- CA2 Dutch founder mutations[J]. Journal of Medical C:netics, 2014, 51(2): 98-107.
7BOLTON KL, CHENEVIX-TRENCH G, GOH C, et at. Associa- tion between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer[J]. Jama, 2012, 307 (4): 382-389.
8Cancer Genome Atlas Research Network. Inte graled genomic analyses of ovarian carcinoma[J]. Nature, 2011, 474(7353): 609- 615.
9GALLAGHER D J, KONNER JA, BELL-MCGUINN KM, et al. Survival in epithelial ovarian cancer: a multivariate analysis in- corporating BRCA mutalion status and platinum sensitivity [J]. Annals of Oneology, 2011, 22(5): 1127-1132.
10KRIVAK TC, DARCY KM, TIAN C, et al. Relationship be- tween ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase 1I Trim of intraperi- toneal versus intravenous cisplatin and paclitaxel for stage m epithelial ovarian cancer[J]. Journal of Clinical Oncology, 2008, 26(21): 3598-3606.